We are live on ! Find out more
MDCO

Medicines Co
MDCO

Delisted

MDCO was delisted on the 3rd of January, 2020.

152 hedge funds and large institutions have $1.52B invested in Medicines Co in 2014 Q3 according to their latest regulatory filings, with 19 funds opening new positions, 66 increasing their positions, 50 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

32% more repeat investments, than reductions

Existing positions increased: 66 | Existing positions reduced: 50

0% more funds holding

Funds holding: 152152 (0)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

0% more first-time investments, than exits

New positions opened: 19 | Existing positions closed: 19

23% less capital invested

Capital invested by funds: $1.97B → $1.52B (-$453M)

86% less call options, than puts

Call options by funds: $1.81M | Put options by funds: $13M

Holders
152
Holders Change
Holders Change %
0%
% of All Funds
4.41%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.03%
New
19
Increased
66
Reduced
50
Closed
19
Calls
$1.81M
Puts
$13M
Net Calls
-$11.2M
Net Calls Change
-$10.5M
Name Holding Trade Value Shares
Change
Change in
Stake
PA
26
Pinnacle Associates
New York
$10.5M -$4.96M -195,155 -29%
Norges Bank
27
Norges Bank
Norway
$9.14M -$10.4M -409,518 -50%
Principal Financial Group
28
Principal Financial Group
Iowa
$9.07M -$118K -4,633 -1%
Geode Capital Management
29
Geode Capital Management
Massachusetts
$8.51M +$32.9K +1,295 +0.3%
Charles Schwab
30
Charles Schwab
California
$7.6M +$598K +23,532 +7%
Federated Hermes
31
Federated Hermes
Pennsylvania
$7.27M -$284K -11,180 -3%
OAM
32
Oxford Asset Management
United Kingdom
$7.16M +$8M +314,961 New
TCIM
33
TIAA CREF Investment Management
New York
$7.13M -$181K -7,110 -2%
Ameriprise
34
Ameriprise
Minnesota
$6.35M +$283K +11,142 +4%
PAM
35
Panagora Asset Management
Massachusetts
$6.24M +$699K +27,519 +11%
ACM
36
Ashford Capital Management
Delaware
$6.17M +$211K +8,300 +3%
Goldman Sachs
37
Goldman Sachs
New York
$6M -$3.69M -145,431 -35%
Deutsche Bank
38
Deutsche Bank
Germany
$5.94M +$732K +28,829 +12%
Retirement Systems of Alabama
39
Retirement Systems of Alabama
Alabama
$5.65M +$6.43M +253,000 New
Schroder Investment Management Group
40
Schroder Investment Management Group
United Kingdom
$5.34M -$112K -4,400 -2%
BIM
41
BlackRock Investment Management
Delaware
$4.84M +$25K +986 +0.5%
Bank of Montreal
42
Bank of Montreal
Ontario, Canada
$4.84M -$3.03M -119,203 -35%
California Public Employees Retirement System
43
California Public Employees Retirement System
California
$4.76M +$27.9K +1,100 +0.5%
TC
44
TFS Capital
Pennsylvania
$4.09M +$2.67M +105,244 +135%
GC
45
Guggenheim Capital
Illinois
$4.05M +$285K +11,203 +7%
QBFM
46
QS Batterymarch Financial Management
New York
$3.87M -$411K -16,170 -9%
ECP
47
Elk Creek Partners
Colorado
$3.72M +$899K +35,393 +27%
AllianceBernstein
48
AllianceBernstein
Tennessee
$3.66M +$807K +31,780 +24%
Morgan Stanley
49
Morgan Stanley
New York
$3.63M +$2.35M +92,686 +132%
Bank of America
50
Bank of America
North Carolina
$3.59M +$2.49M +97,979 +156%

MDCO Hedge Fund Activity: Q3 2014 in Review

152 of the 3,446 institutional investors tracked by Wall St. Rank reported a position in Medicines Co (MDCO) for Q3 2014, worth a combined $1.52B — down 23% from $1.97B a quarter earlier.

Fund positioning in MDCO was balanced in Q3 2014: 19 funds opened new positions, 19 closed out, 66 added to existing stakes and 50 trimmed.

The largest buyer was Bridger Management, adding an estimated $31.7M. The largest seller was PointState Capital, cutting an estimated $36.3M.

  • 152 institutional investors held Medicines Co (MDCO) as of Q3 2014, unchanged from Q2 2014.
  • Funds reported $1.52B of Medicines Co stock for Q3 2014, down 23% quarter-over-quarter.
  • 19 funds opened new Medicines Co positions in Q3 2014 and 19 closed out, a net change of 0 holders.
  • The largest Medicines Co buyer in Q3 2014 was Bridger Management, an estimated $31.7M added.
  • The largest Medicines Co seller in Q3 2014 was PointState Capital, an estimated $36.3M sold.

Based on aggregated 13F filings for Q3 2014.